Early Developability Assessment
Inquiry
Developability assessment is a systematic early-stage evaluation to determine whether a candidate molecule can be successfully developed into a stable, safe, and manufacturable drug. Leveraging our deep expertise in oncology, Alfa Cytology offers a suite of developability services designed to de-risk your drug discovery programs. From small molecules to complex biologics, our platforms provide the critical data needed to select the best candidates for success.
Introduction to Developability Assessment
Developability refers to the potential of an active compound to possess ADME properties and safety profiles sufficient to enter clinical studies. In the long journey of drug discovery and development, developability assessment serves as the first critical checkpoint determining project success or failure. Statistics show that only approximately 1% of laboratory-stage candidate molecules ultimately reach market approval, and over 60% of candidate drug failures are attributed to suboptimal ADME/T properties or developability issues—rather than a lack of pharmacological activity. Before committing to costly in vivo studies and CMC development, systematic developability assessment of candidate molecules enables you to:
- Identify development risks early, avoiding wasted time and resources on candidates destined to fail in later stages.
- Provide directions for molecular optimization, guiding structural modifications to improve critical attributes.
- Support informed candidate selection, enabling optimal choices among multiple functionally active molecules.
Fig. 1 Considerations of developability-related measurements at the different stages from target evaluation to IND filing. (Zhang W, et al.; 2022)
Our Services
As a preclinical CRO specializing in oncology, Alfa Cytology offers systematic developability assessment for both small molecules and biologics. We know that early developability assessment in oncology drug development goes beyond molecular properties, it determines whether later efficacy, PK/PD, and toxicology studies will translate into clinical benefit. We help you select the most promising candidates before CMC and IND-enabling toxicology studies begin.
Biologics Developability Assessment
We provide systematic, molecule property-based developability assessment for a broad range of biologics (monoclonal antibodies, bispecific antibodies, fusion proteins, ADCs, gene therapy vectors, and more), covering in silico analysis, physicochemical characterization, non-specific binding evaluation, and stability stress testing.
Tumor Model Library
We provide multi-cancer, multi-type tumor model development and construction services, alongside a rigorously validated repository of established models—offering solid support for the efficacy evaluation of both small molecules and biologics.
In Vitro Cell Models
Covering >100 human tumor cell lines, supporting in vitro efficacy screening, IC50 determination, ADC internalization and cytotoxicity assessment, and combination synergy evaluation (Chou-Talalay method), among others.
CDX Models
Covering major solid tumors and hematological malignancies, with all cell lines authenticated by STR profiling. Features include drug-resistant models (acquired/primary resistance) and targeted mutation-driven models (EGFR, KRAS, BRAF, HER2, etc.).
PDX Models
Directly derived from clinical tumor specimens, faithfully preserving the histopathological features, genetic heterogeneity, and microenvironment composition of the original tumors. Accompanied by genomic profiling data and historical drug response records.
Orthotopic Models
Tumor cells or tissues are implanted into the corresponding anatomical sites (lung orthotopic, mammary fat pad, intracranial, etc.), more closely recapitulating the native tumor microenvironment—ideally suited for studies on tumor invasion and metastasis.
Metastatic Models
Covering lung metastasis, bone metastasis, liver metastasis, and brain metastasis, established via tail vein injection, intrasplenic injection, intracardiac injection, or orthotopic implantation.
Immuno-Oncology Models
Covering syngeneic models (MC38, CT26, B16F10, EMT6, 4T1, etc.), humanized immune system-reconstituted mice (Hu-PBL, Hu-HSC), and PDX-plus-humanized-immune dual models—comprehensively supporting in vivo efficacy evaluation of immune checkpoint inhibitors, bispecific antibodies, and other immunotherapies.
Areas of Expertise in Oncology
As a preclinical CRO specializing in oncology, our developability assessment platforms have been extensively validated across a broad spectrum of malignancies. We provide comprehensive service capabilities spanning small molecules, biologics, and ADCs, covering both solid tumors and hematological malignancies with deep domain expertise.
Breast Cancer
Cervical Cancer
Esophageal Cancer
Melanoma
Pancreatic Cancer
Pharyngeal Cancer
Service Highlights
- Dual-Platform Coverage – Simultaneously equipped with both small molecule and biologics developability assessment capabilities, addressing diverse client needs.
- Early-Stage Risk Mitigation – Identifies potential risks at the earliest stage of R&D, significantly reducing downstream development costs.
- Data-Driven Decision Making – Provides clear go/no-go decision criteria grounded in rigorous scientific data.
- End-to-End Solution– Assessment results seamlessly link to subsequent pharmacology, DMPK, and safety evaluation services.
Early, data-driven developability assessment is the key to identifying the most promising candidates and avoiding costly late-stage failures. Whether you are developing small molecules or biologics, our team of experienced scientists at Alfa Cytology is ready to provide tailored solutions that align with your project goals and timelines. Please contact our expert team today to discuss your specific program needs and learn how we can accelerate your drug discovery journey.
Reference
- Zhang W, et al. Developability assessment at early-stage discovery to enable development of antibody-derived therapeutics. Antib Ther. 2022;6(1):13-29.
For research use only.
Related Services
